New Compound Targets The Neuronal Epigenome To Treat Alzheimer's Disease

A squad from nan University of Barcelona has designed and validated successful animal models an innovative compound pinch a pioneering system of action for nan curen of Alzheimer's disease. Unlike existent drugs, which chiefly region beta-amyloid plaques that accumulate successful nan brain, this caller experimental supplier reprogrammes nan neuronal epigenome by correcting alterations successful cistron look that lend to nan progression of nan disease. The results of this study, published successful Molecular Therapy, unfastened nan doorway to an epigenetic-based therapeutic strategy to conflict Alzheimer's disease.

The compound FLAV-27 represents an innovative and promising attack to Alzheimer's disease, pinch nan imaginable to modify nan illness process, arsenic it acts not only connected its symptoms aliases a azygous pathological biomarker, but straight connected its underlying molecular mechanisms."

Aina Bellver, interrogator astatine nan UB Institute of Neurosciences (UBneuro) and first writer of nan paper

The study was led by Professor Christian Griñán and Professor Mercè Pallàs, from nan Faculty of Pharmacy and Food Sciences, pinch nan information of researchers from UBneuro and nan CIBER Area for Neurodegenerative Diseases (CIBERNED), arsenic good arsenic nan UB Institute of Biomedicine (IBUB), nan Institute of Nutrition and Food Safety (INSA-UB), nan August Pi one Sunyer Biomedical Research Institute (IDIBAPS) and different nationalist and world institutions.

Beyond beta-amyloid protein: a caller epigenetic target

The narcotics presently approved to dainty Alzheimer's, specified arsenic lecanemab and donanemab, are monoclonal antibodies that activity by removing beta-amyloid macromolecule plaques from nan brain. "Although they correspond a breakthrough, their efficacy is limited, arsenic they only slow cognitive diminution by 27% to 35%, person respective broadside effects and only reside nan portion of nan pathology caused by beta-amyloid accumulation," nan researchers explain.

In contrast, FLAV-27 useful successful a wholly different way: it is nan first inhibitor successful its people to impact nan G9a enzyme, which is basal successful nan epigenetic regularisation of nan encephalon because it helps to soundlessness genes that are basal for neuronal development, synaptic plasticity and representation consolidation.

To inhibit G9a, nan caller supplier prevents entree by nan earthy molecule S-adenosylmethionine (SAM), which nan enzyme needs to modify DNA. It frankincense slows down nan epigenetic dysregulation, characteristic of Alzheimer's disease, and allows neurons to regain normal function.

Functional cognitive betterment successful animal models

The study shows that inhibiting G9a pinch FLAV-27 not only reduces classical pathological markers, specified arsenic beta-amyloid macromolecule and phosphorylated tau, which accumulate successful nan brains of group pinch Alzheimer's disease, but besides restores cognitive function, societal behaviour and nan building of neuronal synapses successful various models: from successful vitro assays, done nan worm C. elegans — successful which it improves mobility, life expectancy and mitochondrial respiration — to murine models of late-onset and early-onset Alzheimer's disease. "In these models, location is grounds of improved short- and semipermanent memory, spatial representation and sociability, which demonstrates not only an effect connected molecular markers, but besides functional cognitive recovery," nan researchers emphasize.

According to nan authors, these results corroborate that epigenetic dysregulation — changes successful nan chemic mechanisms that find which genes are activated aliases not without altering nan DNA series — is not conscionable a broadside effect of Alzheimer's disease, but an progressive and controllable system that links nan main pathological features of nan disease, specified arsenic beta-amyloid and tau proteins, neuroinflammation and synaptic dysfunction, done a communal epigenetic axis.

This opens nan doorway to a caller class of therapies: epigenetic disease-modifying treatments, which could complement aliases moreover switch existent strategies, which are based exclusively connected nan elimination of beta-amyloid.

Blood biomarkers to show treatment

A cardinal uncovering that adds to nan translational worth of this curen is nan recognition of a biomarker that tin beryllium measured successful some nan encephalon and humor plasma of patients. The squad has recovered that nan epigenetic marker H3K9me2, nan SMOC1 macromolecule and nan p-tau181 molecule are importantly elevated and that their humor levels correlate straight pinch symptoms specified arsenic tau macromolecule accumulation, neuroinflammation and nan grade of cognitive impairment. When FLAV-27 is administered successful animal models, these indicators return to normal levels, successful parallel pinch cognitive recovery.

The readiness of these peripheral bioindicators is 1 of nan cardinal aspects that distinguishes FLAV-27 from different narcotics successful development. "It has important implications for early objective trials, arsenic it will let nan action of suitable patients pinch a elemental humor test, monitoring of curen and objection that nan supplier really modifies its therapeutic target," nan authors stress.

Towards quality trials: nan spin-off Flavii Therapeutics

Despite these promising results, FLAV-27 still needs to walk further stages earlier objective tests tin statesman successful humans. Currently successful nan precocious preclinical phase, nan adjacent steps see regulatory toxicology studies successful astatine slightest 2 animal species, obtaining nan pharmaceutical form, and preparing nan regulatory dossier to use for objective proceedings authorization from nan applicable agencies, a process that will return years.

This caller shape will beryllium led by Flavii Therapeutics, a spin-off from nan UB founded successful 2025 and holder of nan exclusive licence for FLAV-27. The institution will return connected nan preclinical and objective improvement of nan drug, arsenic good arsenic nan guidance of intelligence spot and fundraising, pinch nan purpose of converting nan knowledge generated astatine nan UB into caller therapies for cardinal nervous system diseases specified arsenic Alzheimer's.

The study is nan consequence of collaboration betwixt nan UB and respective world centres and universities, specified arsenic nan Universitat Autònoma de Barcelona, nan University of A Coruña, Universitat Internacional de Catalunya, nan CIBER Area for Physiopathology of Obesity and Nutrition (CIBEROBN), nan University of Santiago de Compostela, nan Hospital de la Santa Creu one Sant Pau, nan Southern Headquarters Unit of nan Centre for Research and Advanced Studies of nan National Polytechnic Institute (Cinvestav) successful Mexico, nan Medical Campus of nan University of Colorado Anschutz (United States), University College London (United Kingdom), Quaid-i-Azam University (Pakistan) and nan Central University of Rajasthan (India).